Acquired Resistance Forum Video #9: Dr. Alice Shaw of Massachusetts General Hospital detailed for patients the so-called "next generation" ALK/ROS1 inhibitors, both those commercially available and those still in development.

Dr. Robert Doebele of the University of Colorado Cancer Center spoke to ALK and ROS1 patients about how and why their cancers become resistant to treatment and what options are available.

Dr. Robert Doebele explains why he feels that repeat biopsies help researchers better understand why ALK+ lung cancer patients become resistant to current treatments - and why some do better than expected. February 2014

[powerpress]

The doctors discuss the new FDA-approved drug for ALK positive lung cancer patients, Zykadia (ceritinib), including the dosage level, potential side effects and the ability of Zykadia to impact brain metastases.

[powerpress]

Xalkori (crizotinib) has had great success treating ALK positive lung cancer patients. The next generation of ALK inhibitors are also showing great promise. In this video, Dr. Leena Gandhi of Dana-Farber Cancer Institute talks about the research.

[powerpress]

This is a slide presentation I did last week at a local conference, describing the steady, incremental improvements in survival with advanced/metastatic non-small cell lung cancer (NSCLC) that have occurred over the past 10-15 years.

Yesterday, the FDA approved the oral second generation ALK inhibitor LDK378, also known as ceritinib and newly christened Zykadia, for ALK-positive NSCLC who have progressed on or are intolerant of XALKORI (crizotinib).

Several new treatments for ALK positive lung cancer patients are on the horizon. In this video, the doctors discuss them while patients in the audience share some of their experiences with side effects on various treatments.

[powerpress]

(IE/Firefox Users: If you have playback problems, please view on YouTube or try the "Download" button above. Get the latest QuickTime Player.)